Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) - Total Liabilities

Latest as of September 2025: CN¥1.86 Billion CNY ≈ $272.82 Million USD

Based on the latest financial reports, Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has total liabilities worth CN¥1.86 Billion CNY (≈ $272.82 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Suzhou Zelgen Biopharmaceuticals Co Ltd - Total Liabilities Trend (2016–2024)

This chart illustrates how Suzhou Zelgen Biopharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Suzhou Zelgen Biopharmaceuticals Co Ltd Competitors by Total Liabilities

The table below lists competitors of Suzhou Zelgen Biopharmaceuticals Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Krishna Institute of Medical Sciences Limited NSE:KIMS	India	Rs52.00 Billion
Angel One Limited NSE:ANGELONE	India	Rs125.10 Billion
Sichuan Chemical Co Ltd SHE:000155	China	CN¥14.81 Billion
Hebei Changshan Biochem Pharma SHE:300255	China	CN¥3.18 Billion
Cofinimmo SA BR:COFB	Belgium	€2.88 Billion
Weihai Guangwei Composites Co Ltd SHE:300699	China	CN¥3.29 Billion
Ardentec TWO:3264	Taiwan	NT$18.12 Billion
Renasant Corporation NYSE:RNST	USA	$22.90 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Suzhou Zelgen Biopharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Suzhou Zelgen Biopharmaceuticals Co Ltd stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.85	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.62	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.62	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Suzhou Zelgen Biopharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Suzhou Zelgen Biopharmaceuticals Co Ltd (2016–2024)

The table below shows the annual total liabilities of Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥1.75 Billion ≈ $256.37 Million	+41.02%
2023-12-31	CN¥1.24 Billion ≈ $181.80 Million	+41.05%
2022-12-31	CN¥880.82 Million ≈ $128.89 Million	+78.71%
2021-12-31	CN¥492.88 Million ≈ $72.12 Million	+76.85%
2020-12-31	CN¥278.69 Million ≈ $40.78 Million	+13.05%
2019-12-31	CN¥246.52 Million ≈ $36.07 Million	+42.30%
2018-12-31	CN¥173.24 Million ≈ $25.35 Million	+132.21%
2017-12-31	CN¥74.61 Million ≈ $10.92 Million	+168.71%
2016-12-31	CN¥27.76 Million ≈ $4.06 Million	--

About Suzhou Zelgen Biopharmaceuticals Co Ltd

SHG:688266 China Biotechnology

Market Cap

$3.47 Billion

CN¥23.74 Billion CNY

Market Cap Rank

#4592 Global

#797 in China

Share Price

CN¥89.69

Change (1 day)

+3.09%

52-Week Range

CN¥75.75 - CN¥133.48

All Time High

CN¥133.48